A new hi-tech prostate cancer drug has already demonstrated a 'positive impact on the quality of life', the Institute of Cancer Research said today, as the treatment trials in the capital.
Professor Johann de Bono from the institute, who led the Affirm trial, said:
"Enzalutamide is a much needed development in prostate cancer treatment and will provide a new option for the increasing number of men with advanced prostate cancer in the UK whose disease has become resistant to first-line hormonal treatments and who have had docetaxel chemotherapy.
"Enzalutamide has already demonstrated a positive impact on quality of life whilst increasing the life-span of patients with this common disease.
"It's use will bring significant benefits, establishing it as a key component of advanced prostate cancer treatment in the UK."
More top news
A teenager has been arrested after a mass bomb hoax closed hundreds of schools across the UK.
The Metropolitan Police have confirmed the charge following his arrest on Sunday. He will appear at Wimbledon Magistrates’ Court on April 4.
Declan Donnelly will host the show alone when the show returns on March 31 following his partner Ant McPartlin's return to rehab, ITV says.